Key Takeaways

  • Mogrify reported statistically significant preservation and restoration of visual function in a rodent model of retinal degeneration

  • The investigational therapy uses AAV-delivered transcription factors to reprogram Müller glial cells into functional photoreceptors

  • The company plans to present its findings at FLORetina-ICOOR 2026 and is seeking partners to advance the program toward first-in-human studies

Mogrify announced plans to present preclinical proof-of-concept data demonstrating preservation and restoration of visual function using its investigational retinal regeneration therapy at the FLORetina-ICOOR 2026 Congress, scheduled for December 3–6, 2026.

The company's lead program uses transcription factor-mediated direct reprogramming to convert Müller glial cells into functional photoreceptors within the retina. The approach is designed to address photoreceptor loss associated with retinal degeneration and potentially restore vision across multiple retinal disorders.

In a recently completed large-scale preclinical study, Mogrify reported statistically significant preservation and restoration of visual function across multiple functional endpoints in a rodent model of induced retinal degeneration. The study evaluated adeno-associated virus (AAV)-delivered combinations of transcription factors identified using the company's proprietary platform.

The platform integrates next-generation sequencing with human gene regulatory network analysis to identify transcription factor combinations capable of directing cell fate changes.

Jonathan Appleby, PhD, chief scientific officer at Mogrify, said the findings demonstrated the potential of AAV-delivered transcription factors to both protect against and reverse vision loss in a preclinical model.

"Demonstrated across several dosing formats and multiple functional endpoints, these findings represent an important step towards the development of a fundamentally novel and gene-agnostic approach to treating retinal disease," Dr. Appleby said.

Dr. Appleby will lead the program toward first-in-human studies. Mogrify is currently exploring licensing, investment, and partnership opportunities to support clinical development.

The presentation, titled "Delivery of a Selected Combination of Transcription Factors Can Improve Visual Function in a Preclinical Model of Retinal Degeneration," is scheduled for December 3, 2026, from noon to 1 p.m., during the IRD 1 – Natural History, Endpoints & Therapies session.

The findings will also be presented during The Dolphin Tank, an ophthalmology and vision science innovation showcase hosted by Eyenovate during the congress.